BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• 

  Mollie Barnes

  Mollie Barnes is a freelance science writer. Reach her at mollie@100yearsco.com. Follow her on Threads and Instagram @shejustlikedtogo or LinkedIn. See more of her work at molliebarnes.contently.com.
• 

  Mergers & Acquisitions

  Mallinckrodt Offloads Therakos Photopheresis Business to CVC Capital Partners for $925M

  The specialty pharmaceutical company has twice filed for bankruptcy in recent years, driven by opioid-related litigation. Mallinckrodt’s deal with CVC will allow it to pay off more than half of its net debt.

  August 6, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Career Advice

  Manager’s Toolbox: Exploring Empathy, Intellectual Curiosity, and Vulnerability

  Whether they’re newly minted managers or C-suite executives, effective managers often lead with empathy, intellectual curiosity and vulnerability.

  August 6, 2024

   · 

  5 min read

   · 

  Bruce Wu
• 

  Gene therapy

  BioMarin Narrows Roctavian Efforts to U.S., Germany, Italy as Sales Stagnate

  BioMarin Pharmaceuticals on Monday said it is restricting sales of its hemophilia A gene therapy to three countries in an effort to reduce costs and help the treatment become profitable by 2025.

  August 6, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cancer

  Actinium to Farm Out AML Radioactive Drug After FDA Asks for Another Trial

  The FDA is looking for stronger overall survival data to back Actinium’s application for Iomab-B, an investigational therapy that will allow acute myeloid leukemia patients to receive bone marrow transplants.

  August 6, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Bayer Touts ‘Modest’ Q2 Performance Amid Sweeping Reorganization

  Bayer’s surprising growth in the second quarter was driven in large part by two pharma products: the prostate cancer drug Nubeqa and the chronic kidney disease treatment Kerendia.

  August 6, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Daiichi Pays Merck $170M for T-Cell Engager, Expands ADC Partnership

  After dropping $4 billion on a deal with the Japanese company last year, Merck is getting back some of its investment as Daiichi Sankyo buys into a Phase I/II T-cell engager therapy acquired from Harpoon Therapeutics.

  August 6, 2024

   · 

  1 min read

   · 

  Kate Goodwin
• 

  Deals

  Cash-Strapped Sangamo Gets Lifeline from Genentech in Potential $1.9B Neuro Deal

  Sangamo Therapeutics announced Tuesday it secured an exclusive licensing agreement with Roche’s Genentech, which is paying $50 million in near-term upfront fees and milestone payments to develop novel genomic medicines for neurodegenerative diseases.

  August 6, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Funding

  Symbiotic Capital Launches With More Than $600M to Provide Life Science Loans

  Biotech entrepreneur Arie Belldegrun and former Roche CEO Franz Humer are part of the credit firm’s push to provide companies with another source of funding, Symbiotic Capital announced Tuesday.

  August 6, 2024

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Drug Development

  Applying AI in Today’s Reality of QARA Processes

  In this live panel discussion, speakers explore artificial intelligence in medtech and practical realities in QARA. An executive summary is available.

  August 6, 2024

   · 

  1 min read

   · 

  Lori Ellis